Loading…
← CockpitCompetitor Analysis › QUIT Achieve Life Sciences, Inc.Open in the cockpit ↗

Achieve Life Sciences, Inc.QUITCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Mkt cap
$609M
US dollars, full cap
Free float
68%
of shares outstanding
$/day
$5.98M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 16.9%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · USD$5.92
1D-3.3%
1W-8.2%
1Mn/a
3Mn/a
6Mn/a
YTDn/a
1Yn/a

What Achieve Life Sciences does

Employees: 28

Achieve Life Sciences at a glance

Size Achieve Life Sciences (QUIT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $609M, the 2544th largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.92 on 18 Nov 2026.

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Achieve Life Sciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$235,000-$228,000-$229,000-$228,000-$236,000
EBITDA-$63.9M-$54.7M-$38.8M-$27.0M-$40.6M
Net income-$112M-$54.6M-$39.8M-$29.8M-$42.4M
Free cash flow-$44.1M-$49.5M-$29.8M-$24.5M-$37.6M
Capital expenditure$222,000$3,000$0$21,000$0
Total debt$14.0M$15.0M$9.96M$16.7M$16.2M

Quarterly statements and history in the cockpit →

Achieve Life Sciences competitors and peer comparison

How Achieve Life Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%

Questions

Which companies are Achieve Life Sciences's closest peers?
The cockpit's peer set: Luoxin Pharmaceuticals Group Stock (002793.SZ), Chongkundang (185750.KS), HeiLongJiang ZBD Pharmaceutical (603567.SS), Zhejiang Anglikang Pharmaceutical (002940.SZ), Fuan Pharmaceutical (Group) (300194.SZ), Orchid Pharma (ORCHPHARMA.NS), TTY Biopharm (4105.TWO), DBV Technologies (DBV.PA).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.